motixafortide [5300]



motixafortide


SMILES N=C(N)NCCC[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(N)=O)C(=O)N1)C(N)=O
InChIKey JJVZSYKFCOBILL-MKMRYRNGSA-N
Sequence RRXCYXKKPYRXCR
HELM PEPTIDE1{[*C(=O)[C@H](CCCNC(=N)N)NC(=O)c1ccc(cc1)F |$_R2;;;;;;;;;;;;;;;;;;;;$|].R.[Nal].C.Y.[Cit].K.K.P.Y.R.[Cit].C.R.[am]}$PEPTIDE1,PEPTIDE1,4:R3-13:R3$$$

Chemical Properties

Hydrogen bond acceptors 27
Hydrogen bond donors 34
Rotatable bonds 49
Log P -4.886
Molecular weight (Da) 2158.1
Stereochemistry info unspecified


No bioactivity data available.

motixafortide


Drug properties

Molecular type Peptide
Physiological/Surrogate Surrogate
Approved drug Yes

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0


Compound is not listed as a drug.